Tolerable and curable treatment in HIV/HCV co-infected patients using anti-HCV direct antiviral agents: a real-world observation in China
Tolerable and curable treatment in HIV/HCV co-infected patients using anti-HCV direct antiviral agents: a real-world observation in China
复制标题
使用抗 HCV 直接抗病毒药物治疗 HIV/HCV 合并感染患者的耐受性和可治愈性：中国的真实世界观察
DOI：
10.1007/s12072-018-9891-9
复制
发表时间：
2018-09-01
影响因子：
6.6
通讯作者：
Wang, Fu-Sheng
中科院分区：
文献类型：
--
作者：
Li, Yuanyuan;Li, Linghua;Wang, Fu-Sheng
目的：目前中国尚无品牌直接作用抗病毒药物（DAAs）用于治疗HIV-1/HCV合并感染患者。本研究旨在观察仿制DAAs对中国患者的疗效和安全性。设计真实世界环境以阐明DAAs在HIV-1/HCV合并感染患者中是否耐受和有效。方法对176例HIV-1/HCV合并感染患者进行抗HCV DAA联合ART治疗。176例患者中，有99例患者采用SOF+DCVRBV治疗，60例患者采用SOF+LDVRBV治疗，17例患者采用SOF+RBV +/- Peg-IFN治疗，疗程分别为12周和24周。主要终点是治疗完成后12周无法检测到HCV RNA （SVR12）。分析有关安全性和不良事件的数据。结果1/176例HIV-1/HCV合并感染患者均完成治疗并随访12周。sofa +DCV、sofa +DCV+RBV、sofa +Peg-IFN+RBV、sofa +RBV、sofa +LDV、sofa +LDV+RBV治疗12周或24周患者的SVR12分别为100%（75/75）、100%（11/11）、100%（14/14）、100%（2/2）、95.2%（40/42）、100%（7/7）。HIV-1/HCV合并感染的肝硬化患者获得了良好的SRV12。值得注意的是，在接受有或没有Peg-IFN和RBV的DAA方案的患者中，具有不同基线CD4(+) t细胞计数的患者的不良反应没有显着差异。结论：sofv +DCV和sofv +LDV方案耐受性好，疗效高。患者的基线CD4(+) t细胞计数在不良反应中没有显着差异。
ObjectiveNo brand direct-acting antiviral agents (DAAs) are available for treatment of HIV-1/HCV co-infected patients in China. This study aimed to observe the therapeutic efficacy and safety of generic DAAs for affected Chinese patients.DesignReal-world setting to elucidate whether DAAs were tolerated and effective in HIV-1/HCV co-infected patients.Methods176 HIV-1/HCV co-infected patients received anti-HCV DAA treatment together with ART regimens for HIV infection. Among the 176 patients, 99 patients were treated with SOF+DCVRBV, 60 patients were treated with SOF+LDVRBV, and 17 patients received SOF+RBV +/- Peg-IFN regimens, for 12 or 24weeks, respectively. The primary endpoint was undetectable HCV RNA 12weeks after therapy was completed (SVR12). Data pertaining to safety and adverse events were analyzed.Resultsp id=Par4151/176 HIV-1/HCV co-infected patients finished the treatment and 12-week follow-up. SVR12 for the patients treated with regimens of SOF+DCV, SOF+DCV+RBV, SOF+Peg-IFN+RBV, SOF+RBV, SOF+LDV, and SOF+LDV+RBV for 12 or 24weeks was 100% (75/75), 100% (11/11), 100% (14/14), 100% (2/2), 95.2% (40/42), and 100% (7/7), respectively. HIV-1/HCV co-infected patients with liver cirrhosis achieved well SRV12. Notably, there was no significant difference in adverse effects among patients with different baseline CD4(+) T-cell count in those who received DAA regimens with or without Peg-IFN and RBV.Conclusion p id=Par5 We showed generic SOF+DCV and SOF+LDV regimens were well tolerated and with high efficiency. Patient's baseline CD4(+) T-cell count did not exhibit significant difference in adverse effects.